Mersana Therapeutics: FDA Grants Additional Fast Track Designation To XMT-1660

(RTTNews) - Mersana Therapeutics (MRSN) announced the FDA recently granted an additional Fast Track designation to XMT-1660. The new Fast Track designation is for the treatment of advanced or metastatic breast cancer in patients with human epidermal growth factor receptor 2 low or HER2-negative disease. The company also announced that the World Health Organization has approved emiltatug ledadotin as XMT-1660s international nonproprietary name.

Separately, Mersana Therapeutics announced positive initial clinical data from the Phase 1 dose escalation and backfill cohorts for emiltatug ledadotin, Mersanas lead Dolasynthen ADC candidate targeting B7-H4.

"We believe the initial safety, tolerability and efficacy data for Emi-Le demonstrate a profile that is exciting and differentiated within both the B7-H4 field and the broader ADC landscape, said Martin Huber, CEO of Mersana Therapeutics.

For More Such Health News, visit rttnews.com.